Group items tagged

The Small Business Innovation Research (SBIR) Program stimulates technological innovation in the private sector by strengthening the role of small business concerns in meeting Federal research and development needs, increasing the commercial application of federally supported research results, and fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses. The SBIR program solicits proposals from the small business sector consistent with NSF's mission. The program is governed by Public Law 112-81 (SBIR/STTR Reauthorization Act of 2011). A main purpose of the legislation is to stimulate technological innovation and increase private sector commercialization. The NSF SBIR program is therefore in a unique position to meet both the goals of NSF and the purpose of the SBIR legislation by transforming scientific discovery into both social and economic benefit, and by emphasizing private sector commercialization. Accordingly, NSF has formulated broad solicitation topics for SBIR that conform to the high-technology investment sector's interests. The topics are: Biological and Chemical Technologies (BC) Education Applications (EA) Electronics, Information and Communication Technologies (EI) Nanotechnology, Advanced Materials, and Manufacturing (NM)

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.

The Small Business Innovation Research (SBIR) Program stimulates technological innovation in the private sector by strengthening the role of small business concerns in meeting Federal research and development needs, increasing the commercial application of federally supported research results, and fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses. The topics, listed below, are detailed on the SBIR/STTR topics homepage: Educational Technologies and Applications (EA) Information and Communication Technologies (IC) Semiconductors (S) and Photonic (PH) Devices and Materials Electronic Hardware, Robotics and Wireless Technologies (EW) Advanced Manufacturing and Nanotechnology (MN) Advanced Materials and Instrumentation (MI) Chemical and Environmental Technologies (CT) Biological Technologies (BT) Smart Health (SH) and Biomedical (BM) Technologies

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. There is a need for improved tissue preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies. In addition, novel approaches are needed to preserve DNA, RNA, and small molecules during collection and storage of biological samples.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. There is a need for improved tissue preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies. In addition, novel approaches are needed to preserve DNA, RNA, and small molecules during collection and storage of biological samples.

The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of particular interest.

The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of particular interest.

This Funding Opportunity Announcement (FOA) encourages the translation of technologies for biomedical or behavioral research from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnership and close collaboration between the original developers of these technologies and applicant SBCs, which may be accomplished in any of a number of ways, including the use of multiple principal investigators.

The involvement of small businesses in translational aging research could substantially hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults. Therefore, this funding opportunity announcement (FOA) is intended to encourage a greater involvement by small businesses through the SBIR mechanism in transforming scientific advances in aging research into novel devices, products, health care practices and programs that will benefit the lives of older adults. For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical or basic behavioral and social research findings towards the development of new strategies for prevention and treatment of age-related pathologies. T1 translational research approaches could include the development of new research tools or improving existing technologies to diagnose, prevent or treat age-related conditions, functional decline and disability.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress toward integrated long term glucose regulated insulin/pancreatic hormones delivery systems (artificial pancreas).

The SBIR program is congressionally mandated and intended to support scientific excellence and technological innovation through the investment of federal research funds to build a strong national economy by: stimulating technological innovation in the private sector; strengthening the role of small business in meeting federal research and development needs; increasing the commercial application of federally supported research results; and fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses.

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH.

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions.  The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).  

The Office of Research Infrastructure Programs (ORIP) supports research-related resources that create, develop, preserve and supply a variety of high-quality animal models, and related biological materials. ORIP also supports the development and implementation of tools and devices that directly benefit the welfare of research animals, improve handling of laboratory animals, and ease the management of animal facilities. This Funding Opportunity Announcement (FOA) encourages small business concerns to submit Small Business Technology Transfer (STTR) grant applications that propose innovative approaches and technologies to further develop, improve and facilitate the use of animal models and related biological materials, to meet new biomedical challenges related to improvements in the health of humans and the welfare of animal models.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. There is a need for improved tissue preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies. In addition, novel approaches are needed to preserve DNA, RNA, and small molecules during collection and storage of biological samples.  

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells.

The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.  Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects.  The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.   

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. In addition, there is a need for improved tissue fixatives and preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies.

The S&R Foundation Ryuji Ueno Award for Ion Channels or Barrier Function Research was established in 2007 by the American Physiological Society through the generous support of Ryuji Ueno, M.D., Ph.D., Sachiko Kuno, Ph.D., and S&R Foundation.  Dr. Ueno and Dr. Kuno are founders of Sucampo Pharmaceuticals, Inc., and S&R Foundation, both in Bethesda, Maryland. The Ryuji Ueno Award is given annually to an individual demonstrating outstanding promise based on his/her research in ion channels or epithelial barrier function. Applications are accepted from APS members who hold an academic rank of assistant professor or higher or a comparable position if the member is not affiliated with an academic institution. The award of $30,000 is designated for use in the ion channels or epithelial barrier function research program in which the awardee is conducting his/her research. The award does not include any indirect cost reimbursement. The recipient receives complimentary registration to attend the Experimental Biology Meeting and a plaque presented at the Society's Business Meeting. The recipient is expected to attend a Founders' dinner immediately following the APS Business Meeting.

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose development of a broad base of innovative technologies in biomedical computing, informatics, and Big Data Science that will support rapid progress in areas of scientific opportunity in biomedical research. It is expected that this research and development is conducted in the context of important biomedical and behavioral research problems. As such, applications are intended to develop enabling technologies that could apply to the interests of most NIH Institutes and Centers and range from basic biomedicine to research in all relevant organ systems and diseases. Major themes of research include collaborative environments; data integration; analysis and modeling methodologies; and novel computer science and statistical approaches. New opportunities are also emerging as large and complex data sets are becoming increasingly available to the research community.

Eligible applicants that can apply for this FOA are listed below: Government Organizations: * National Ministries of Health * State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) . * American Indian/Alaska Native tribal governments (federally recognized or state-recognized) * Political subdivisions of States (in consultation with States) Non-government Organizations: * American Indian/Alaska native tribally designated organizations * Alaska Native health corporations * Tribal epidemiology centers * Urban Indian health organizations * Nonprofit with 501C3 IRS status (other than institution of higher education) * Nonprofit without 501C3 IRS status (other than institution of higher education) * Research institutions (that will perform activities deemed as non-research) Colleges and Universities Community-based organizations Faith-based organizations For-profit organizations (other than small business) Hospitals Small, minority, and women-owned businesses All Other eligible organizations